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Abstract: Radioimmunotherapy using a radiolabeled monoclonal antibody that targets tumor
cells has been shown to be efficient for the treatment of many malignant cancers, with reduced
side effects. However, the blood–brain barrier (BBB) inhibits the transport of intravenous
antibodies to tumors in the brain. Recent studies have demonstrated that focused ultrasound
(FUS) combined with microbubbles (MBs) is a promising method to transiently disrupt the
BBB for the drug delivery to the central nervous system. To find the optimal FUS and MBs
that can induce reversible increase in the BBB permeability, we employed minimally invasive
multiphoton microscopy to quantify the BBB permeability to dextran-155 kDa with similar
molecular weight to an antibody by applying different doses of FUS in the presence of MBs
with an optimal size and concentration. The cerebral microcirculation was observed through a
section of frontoparietal bone thinned with a micro-grinder. About 5 minutes after applying the
FUS on the thinned skull in the presence of MBs for 1 minute, TRITC (tetramethylrhodamine
isothiocyanate)-dextran-155 kDa in 1% bovine serum albumin in mammalian Ringer’s solution
was injected into the cerebral circulation via the ipsilateral carotid artery by a syringe pump.
Simultaneously, the temporal images were collected from the brain parenchyma ~100–200 μm
below the pia mater. Permeability was determined from the rate of tissue solute accumulation
around individual microvessels. After several trials, we found the optimal dose of FUS. At the
optimal dose, permeability increased by ~14-fold after 5 minutes post-FUS, and permeability
returned to the control level after 25 minutes. FUS without MBs or MBs injected without FUS
did not change the permeability. Our method provides an accurate in vivo assessment for the
transient BBB permeability change under the treatment of FUS. The optimal FUS dose found
for the reversible BBB permeability increase without BBB disruption is reliable and can be
applied to future clinical trials.
Keywords: antibody delivery, multiphoton microscopy, in vivo cerebral microvessel permeability, rat brain
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Macromolecules such as monoclonal antibodies (mAbs) have attracted attention
because of their potential clinical benefits. More recently, mAbs conjugated with radioisotopes, or radioimmunotherapy, administered into the cerebrospinal fluid (CSF), have
proven safe in Phase I clinical trials for the treatment of leptomeningeal cancers (one
type of brain cancer), and the patients survived for extended periods of time.1 While
these studies have been shown to extend life, the methods are less than ideal because
of their invasiveness and slow rate of diffusion from the CSF into the parenchyma.
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Access to the brain parenchyma is characteristically limited
to cells lying close to the ventricles or infusion sites due to
small diffusion distances of drugs and drug carriers through
the interstitial space.2 The surface area of the blood–brain
barrier (BBB) is 5,000 times that of the blood–CSF barrier,
and therefore the BBB is considered to be the primary barrier
controlling the uptake of drugs into the brain parenchyma.3
Thus, a more ideal route of administration would be through
the systemic blood stream if obstacles related to BBB penetration of these macromolecules could be circumvented.
Among the numerous strategies to deliver therapeutic
drugs into the central nervous system, the focused ultrasound
(FUS) sonication combined with microbubbles (MBs) has
been shown to be effective in transiently disrupting the BBB
for noninvasive drug delivery.4–7 At appropriate acoustic
power density (or pressure), burst repetition rate (BRR), duty
cycle, sonication duration, and in the presence of MBs with
proper materials, sizes, and concentrations, FUS can achieve
noninvasive, selective, and localized disruption of the BBB
without visible damage to the brain tissue.8–11
FUS-induced BBB disruption has been widely assessed
by using magnetic resonance imaging (MRI) or post-FUS
histological examination.6,7,12–22 Indirect MRI collects the
images of brain slices in the presence of an MRI contrast
agent such as gadolinium to access the BBB disruption in
different locations of the brain. Alternatively, post-FUS
histological examination relates the BBB disruption to the
amount of Evans blue extravasation in the brain tissue after
the dye is intravenously injected into the blood circulation
before or after sonication. However, the sub-millimeter
spatial resolution of the MRI studies and the postmortem
histological examinations only assess the relatively large
leakage of the BBB, and these methods are restricted to
the exploration of a region that is much larger than a single
microvessel with its surrounding tissue. Therefore, the BBB
disruption assessed by the MRI and histological examination
is more qualitative than quantitative.23,24
To overcome aforementioned limitations, two-photon
microscopy can be employed to quantitatively access the
enhanced permeability of the cerebral vasculature after FUS.25
In addition to micrometer spatial resolution, two-photon
microscopy offers the advantage of deep tissue penetration,
which is essential for the BBB permeability measurement.
However, in the studies from Nhan et al25 the MBs for enhancing the FUS effect and the fluorescently labeled test solutes
were injected via the animal tail vein. This administration
route leads to the uneven distribution of MBs and uncertainty
in the MB concentration in both the FUS-stimulated region
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and in the test solute concentration in cerebral microvessels,
resulting in inaccurate assessments of the dynamics of FUSenhanced BBB permeability. In addition, their study only
estimated the permeability index in a region of ~500 μm ×500
μm containing many types of blood vessels, not the true BBB
permeability at the individual microvessel level.
The objective of the current study was to use our newly
developed multiphoton microscopy23 to more accurately
assess the FUS-induced BBB permeability change in vivo. To
accomplish this aim, MBs were generated and selected for the
optimal size in inducing reversible BBB disruptions.7,15,26,27
Subsequently, the MBs were injected via the carotid artery
at a constant rate to achieve a constant concentration in the
cerebral microvessels in the region of sonication, where the
“optimal” concentration was based on previous studies.6,7,21,28
After FUS in the presence of MBs, tetramethylrhodamine
isothiocyanate (TRITC)-dextran-155 kDa, a model mAbs
macromolecule, was injected via the carotid artery, and
the BBB permeability was determined for an individual
microvessel by a method described by Yuan et al.24 Our
current study enabled us to find optimal FUS and MBs that
can induce reversible increase in the BBB permeability to
macromolecules. These findings will contribute to designing efficient and safe delivery strategies for the brain drug
delivery, particularly for the delivery of antibodies.

Materials and methods
Microbubble preparation
Lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC;
Avanti Polar Lipids Inc., Alabaster, AL, USA) was dissolved in chloroform (Thermo Fisher Scientific, Waltham,
MA, USA). Stabilizing agent polyoxyethylene 40 stearate
(PEG40S; Sigma-Aldrich, St Louis, MO, USA) was dissolved in filtered deionized water (18 MΩ, Direct-Q; EMD
Millipore, Billerica, MA, USA). All solutions were prepared
using 1% bovine serum albumin (BSA) in Ringer’s solution
(pH 7.4–7.45) (see below for the composition), and glassware
was previously cleaned with reagent alcohol (90:5:5 vol%
of ethanol/methanol/isopropanol; Sigma-Aldrich).29,30 MBs
were prepared as previously described.31
MBs having too large sizes may induce harmful effects
such as blocking the blood flow in the pulmonary microvessels, while those having too small sizes may have no effects
on enhancing the BBB permeability.10,11 In order to narrow
down the size distribution of the MBs to near the optimal
size of around 2 μm in diameter,7,10 size isolation was
performed by centrifugation.30 Briefly, MB solution was
placed into a centrifuge (5702R; Eppendorf North America,
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Hauppauge, NY, USA) for 1 minute at 100 RCF (relative
centrifugal force) to remove bubbles larger than ~4 μm.
The infranatant was collected and centrifuged for another
1 minute at 200 RCF to remove bubbles greater than ~3 μm
in diameter. Then, the infranatant was collected again and
centrifuged for 7 minutes at 300 RCF to concentrate all
bubbles with a diameter around ~2 μm.26 The last step was
repeated three times to ensure the complete removal of the
remaining aggregates that did not form MBs. Size distributions were analyzed by using a laser particle size analyzer
(LA-950; Horiba Inc., Irvine, CA, USA). Figure 1 shows the
size distribution curve of the MBs generated by our technique, which have the optimal size of ~2 μm as an ultrasound
contrast agent in in vivo ultrasound imaging and treatment
applications.7,10,11,26,32–34 The MB concentration prepared for
injection was ~1.7×106 bubbles/mL, which is in an optimal
concentration range for reversible disruption of the BBB
based on the study by Yang et al.7

The preparation of the rat skull observation area was the
same as that previously described.23,24 Briefly, the skull in the
region of interest (ROI) was exposed by shaving off the hair
and cutting away the skin and connective tissue. A section
of the frontoparietal bone (either left or right) was carefully
ground with a high speed micro-grinder (0–50,000 rpm, DLT
50KBU; Brasseler USA, Savannah, GA, USA) until a part
of it (~4 mm ×6 mm) became soft and translucent. During
the process, artificial CSF (ACSF) at room temperature was
applied to the surface of the skull to dispel the heat due to
grinding. After grinding, the left or the right carotid artery
was cannulated with PE50 tubing. The rat was then placed
on a stereotaxic alignment system (SAS 597; David Kopf
Instruments, Tujunga, CA, USA), and its head was fixed with
two ear bars and a mouth clamp. After FUS treatment, the
cerebral microvessels were observed under the objective lens
of a multiphoton microscope through the thinned part of the
skull and the BBB permeability was determined.

Animal preparation

Solutions and fluorescent test solute

In vivo experiments were conducted on adult female Sprague
Dawley rats (250–300 g, age 3–4 months; Hilltop Laboratory Animals Inc., Scottsdale, PA, USA). All procedures and
the animal use were approved by the Institutional Animal
Care and Use Committee of the City College of New York.
Rats were anesthetized with pentobarbital sodium injected
subcutaneously (initial dosage 65 mg/kg bodyweight).
A heating pad was used to keep the rat at its body temperature.
The depth of anesthesia was monitored for the absence of
withdrawal reflex to toe pinch and absence of blink reflex.
Anesthesia was further checked every 15 minutes during the
experiment; an additional 3 mg/dose pentobarbital was given
when needed. At the end of the experiments, an overdose of
pentobarbital (100 mg/kg) was administered intravenously
to euthanize the animal.
18

Number (%)
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Mammalian Ringer’s solution was used for all perfusates,
which was composed of (in mM) NaCl 132, KCl 4.6, MgSO4
1.2, CaCl2 2.0, NaHCO3 5.0, glucose 5.5, and HEPES (2-[4(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid) 20.
The pH was buffered to 7.40–7.45 by adjusting the ratio of
HEPES acid to base. In addition, both the washout solution
and the fluorescent dye solution contained 10 mg/mL BSA
(A4378; Sigma-Aldrich).24 The solutions were made fresh on
the day of use to avoid binding to the serum albumin.

ACSF
The ACSF solution composition was (in mM) NaCl 110.5,
KCl 4.7, CaCl2 2.5, KH2PO4 1.1, MgSO4⋅7H2O 1.25, NaHCO3
25, and HEPES 15,35 and the solution was buffered to
pH 7.4±0.5.
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Figure 1 Size distribution of the microbubbles generated in the current study.
Notes: The error bars indicate the standard error of the mean.
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TRITC-dextran-155 kDa (molecular weight 155,000, Stokes
radius ~8.5 nm; Sigma-Aldrich) was used at the concentration
of 1 mg/mL in 1% BSA in Ringer’s solution. The concentration of 1 mg/mL was in the linear range (0–2 mg/mL) of the
concentration versus intensity curve, which was calibrated in
vitro using the same settings as in the in vivo experiments.
All the solutions were oxygenated by bubbling with the
compressed gas composed of 95% oxygen and 5% carbon
dioxide (Airgas; Bethlehem, PA, USA) for 5 minutes before
being injected into the cerebral circulation.
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Ultrasound equipment and calibration
A spherical 1-MHz FUS transducer (Ws50-P50; Ultran, State
College, PA, USA) with a focal length of 50 mm and a focal
area diameter of 3 mm was used in this study. The power was
generated by a function generator (AFG3251; Tektronix Inc.,
Beaverton, OR, USA). An ultrasound power meter (UPMDI-1AV; Ohmic Instruments, Easton, MD, USA) was used
to measure the acoustic pressure generated by the ultrasound
transducer in a degaussed water bath at room temperature.
The acoustic pressure measured was automatically converted
into power by the power meter system.
To determine the relationship of ultrasound power as a function of BRR (in kilohertz) and peak-to-peak voltage (in volts),
powers were measured at varying BRRs (200–1,000 kHz)
and voltages (1–5 V). The duty cycle was kept constant at
5% for tested pulses from 200 to 1,000 kHz. Figure 2 demonstrates the calibration results of the acoustic power density
(power per unit focus area) versus voltage and BRR for the
devices used in the current study. Dots are measured data,
and the surface is the best fitting.

FUS sonication with MBs
Figure 3A illustrates the setup of ultrasound sonication. The
ultrasound probe was placed in a custom-made clear acrylic
adapter and was attached to a stereotaxic alignment system.
The adapter allowed placement of the ultrasound probe in one
end and a rubber-latex sheet (300-series, North; McMaster
Carr, Robbinsville, NJ, USA) in the other. The reservoir water
was degassed with a vacuum pressure pump (Air Cadet 4201901; Thermo Fisher Scientific) at room temperature (25°C).
By implementing the stereotaxic alignment system, the focal
area of the ultrasound probe was easily and accurately located
over the rat’s head by softly pressuring the latex-sheet water

reservoir over the thinned skull. Formation of air bubbles or air
layers between the rat’s skull and the rubber-latex sheet was
avoided by applying an ultrasound transmission gel (National
Medical Alliance, Carmel, IN, USA). After the rat was placed
on the stereotaxic instrument and its head was fixed, the FUS
sonication was applied to the brain through the thinned skull,
while the MBs were injected simultaneously into the carotid
artery at a constant flow rate ~3 mL/min by a syringe pump.
We applied ultrasound at several acoustic powers (in a range
of ~2.85–15.00 W/cm2) with different BRRs and voltages
(Figure 2) to find the proper FUS dose for a reversible increase
of the BBB permeability in the presence of our MBs.

Two-photon microscopy and image
collection
The microvessels were observed with a 40× lens (water
immersion, NA 0.8; Olympus Corporation, Tokyo, Japan),
and the 12-bit images were collected by a two-photon
microscopy system (Ultima; Prairie Technologies Inc.,
Middleton, WI, USA). For TRITC-dextran-155 kDa, the
excitation wavelength of the two-photon microscope was
set to 840 nm.
After ultrasound sonication for ~1 minute in the presence of MBs,6,7 the rat was immediately placed under the
objective of the two-photon microscope. The syringe was
replaced by the one filled with TRITC-dextran-155 kDa
solution (tracer) (Figure 3B). The tracer solution was then
introduced into the cerebral circulation via the carotid
artery at a constant flow rate of ~3 mL/min23,36 for 1 minute
in an interval of 5 minutes. Simultaneously, the images of
the ROI containing the microvessels and the surrounding
brain tissue were captured for 1 minute at 5-minute intervals up to 25 minutes. The images of 239 μm ×239 μm
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Figure 2 Calibration results for the acoustic power density as a function of voltage and burst repetition rate for the focused ultrasound transducer used in the current study.
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A

B
Multiphoton
microscope

Computer

2λ
Pulse
generator

Ear bar

Ultrasound probe
Water reservoir

Tracer
Syringe pump
(Microbubbles)

C

FUS and MB
injection
~1 minute

~5 minutes
Mount to 2P microscopy
and find ROI

~25 minutes
Image collection, ~1 minute every 5 minutes up
to 25 minutes
Injection of fluorescently-labeled solutes
during image collection

Figure 3 Illustrations of experimental setups.
Notes: (A) Schematic of the setup for the ultrasound sonication and MB injection to the cerebral circulation. Sonication on the thinned skull region starts simultaneously
while the MBs are injected through the carotid artery at a rate of ~3 mL/min. (B) Schematic of the blood–brain barrier solute permeability measurement by multiphoton
microscopy. While TRITC-dextran-155 kDa (tracer) is injected through the carotid artery at a rate of ~3 mL/min, the images of the ROI containing several microvessels and
the surrounding brain tissue are collected. Permeability is determined off-line by analyzing the collected images. (C) Experimental timeline and protocol for the FUS sonication
and blood–brain barrier permeability measurement.
Abbreviations: 2P, two-photon; FUS, focused ultrasound; ROI, region of interest; MB, microbubble; TRITC, tetramethylrhodamine isothiocyanate.

(512×512) were collected at a rate of ~1 second per image.
The corresponding resolution is 0.467 μm ×0.467 μm.
The collected images were then transferred to an image
acquisition and analysis workstation to determine the BBB
solute permeability.

Experimental protocol
Figure 3C summarizes the experimental protocol for FUS
effects on the BBB solute permeability. The MBs at a concentration of ~1.7×106 bubbles/mL were injected via rat
carotid artery at a constant speed of ~3 mL/min, the normal
blood flow velocity at the carotid artery; after 10–15 seconds,

International Journal of Nanomedicine 2014:9

the MBs reach the microvascular bed ~100–200 μm below
the pia mater,23 and the FUS sonication was administrated
for 1 minute. After sonication, the rat head was mounted
into the multiphoton microscope, and the ROI with cerebral
microvessels was found. This took about 5 minutes. Then,
the images for determining the BBB solute permeability were
collected for 1 minute at a rate of one image per second in a
5-minute interval, up to 25 minutes. For comparison, three
control experiments were performed: 1) measurement of
permeability in the presence of 1% BSA in Ringer’s solution
only, no MBs and FUS; 2) same protocol, with only MBs;
3) same protocol, with only FUS.

submit your manuscript | www.dovepress.com

Dovepress

4441

Dovepress

Shi et al

Determination of the BBB solute
permeability

2) the dye does not spread out of the window during the time
for permeability measurement (10–60 seconds), and 3) no
dye contamination from the neighboring vessels into the
window. When the criteria were satisfied, permeability was
determined using the equation,24,37

We used the similar method as in our previous study for
permeability of pial microvessels24 to determine permeability
of cerebral microvessels ~100–200 μm below the pia mater.
Most of the microvessels chosen were post-capillary venules
of 15–40 μm diameter for the permeability measurement,
and around 1/4 of the microvessels were capillaries.24,35 The
reasons that we currently only measured the permeability of
post-capillary venules and capillaries were: 1) to avoid the
influence of smooth muscle cells at arteries, arterioles, and
large venules, which would contract under stimuli and affect
the permeability measurement;35 2) our previous studies on
the BBB permeability were also conducted on this type of
post-capillary venules.23,24
The permeability was determined off-line from the
pre-collected images by using ImageJ (National Institutes
of Health, Bethesda, MD, USA). Figure 4A shows a typical image of an ROI (~239 μm ×239 μm) with a couple of
microvessels and surrounding brain tissue. The total fluorescence intensity in a rectangular window including a vessel
lumen and the surrounding tissue (Figure 4A) was measured
by ImageJ. The measuring window was ~50–100 μm long
and ~30–60 μm wide and was set at least 10 μm from the
base of the bifurcation to avoid solute contamination from
the side arms. The criteria for the size and placement of the
measuring window were 1) the vessel segment is straight,

A

P = 1/ΔI0 * (dI/dt)0 * r/2,

where P is permeability, ΔI0 is the step increase of the
fluorescence intensity in the window when the dye just fills
up the vessel lumen (Figure 4B), (dI/dt)0 is the slope of the
increasing curve of the total intensity I versus time t when
the solute further transfers into the surrounding tissue, and
r is the vessel radius.

Corrections for influence of red blood
cells, free dye, and solvent drag on BBB
permeability
The fluorescence dye solution was injected into the brain at
the rate of 3 mL/min, the same as the normal blood perfusion rate.36,38 Although at this perfusion rate the blood was
assumed to be replaced by the fluorescence solution, there
was still residue blood (red blood cells [RBCs]) in the cerebral microvessels, which would overestimate the measured
BBB permeability by ~11%, as estimated in Yuan et al.24
In addition to RBCs, free dye would overestimate the permeability to fluorescently labeled solutes.24,39 The influence

B

6

(dI/dt)0

Intensity (x107)

5

50 μm

(1)

4
3

∆I0

2
1
0
0

20

40

60

80

Time (seconds)
Figure 4 Determination of the blood–brain barrier solute permeability.
Notes: (A) Illustration of the scanning region comprising several microvessels ~100–200 μm below the pia mater. The region area is ~239 μm ×239 μm. The yellow frame
enclosed area is the region of interest used to determine the blood–brain barrier permeability to a solute. (B) Total fluorescence intensity in the region of interest as a
function of perfusion time. Fluorescence intensity in the figure is proportional to the total mass of solute accumulated in the measuring region surrounding the microvessel.
The slope of regression line over the initial linear accumulation (dI/dt)0 (red line) is used to determine permeability P = 1/ΔI0 * (dI/dt)0 * r/2, where ΔI0 (black line with
arrowheads) is the step intensity increase when the dye just fills up the vessel lumen, and r is the radius of the vessel.
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of the free dye on the solute permeability was estimated by
using equation,39
Pcorrect = [1/(1–F)]Pmeasure - [F/(1–F)]Pfreedye,

(2)

where P measure was measured permeability; P freedye was
measured permeability of NaF (14.6×10−7 cm/s),23 since
the molecular weight of TRITC (479) is close to that of
NaF (376); F ~0.3% was the intensity ratio of the free dye
filtrate to the original fluorescently labeled solution for
TRITC-dextran-155 kDa; and Pcorrect was the corrected solute
permeability.
The above apparent permeability P corrected for the
RBCs and free dye still overestimates the true diffusive solute
permeability Pd due to the coupling of solute flux with water
flow (solvent drag). The Pd for TRITC-dextran-155 kDa was
calculated by using the following equations,39,40
P = Pd

pe
exp ( pe − 1)
Pe =

+ L p (1 − σ )∆peff , 

L p (1 − σ ) ∆peff
Pd

,

(3)

(4)

where P is the measured apparent permeability; Pe is the
Péclet number; Lp is the hydraulic conductivity of the
microvessel, which is ~2.0×10−9 cm/s/cm H2O for the cerebral microvessels;23,41 σ is the reflection coefficient of the
microvessel to the solute, and Δpeff is the effective filtration
pressure across the microvessel wall, obtained from
∆peff = ∆p − σ albumin ∆π albumin − σ dye − solute ∆π dye − solute ,  (5)
where Δp and Δπ are the hydrostatic and oncotic pressure differences across the microvessel wall. The superscript dye–solute is TRITC-dextran-155 kDa; σ of rat cerebral microvessels
to the test solutes were estimated based on previous studies24
according to the molecule sizes; σ dextran-155 kDa was estimated
to be 0.96; Δp in the cerebral microvessel was ~10 cm H2O;
and Δπalbumin was 3.6 cm H2O for 10 mg/mL BSA.24

Data analysis and statistics
The BBB permeability to dextran-155 kDa, measured at a
specific time in the control group was used to normalize those
in the test and sham control groups at the same time. Data
were presented as mean ± standard error unless otherwise
specified. Significance was assumed for probability level
P0.05 using a two-way analysis of variance followed by

International Journal of Nanomedicine 2014:9

a Tukey’s post hoc analysis (JMP; SAS Institute Inc., Cary,
NC, USA).

Results
The ultrasound power (voltage, BRR, and duty cycle),
sonication duration, MB size, and MB concentration are
important factors in controlling the BBB-disruption levels
and determining whether the increased BBB permeability
is reversible.6,7,11,15,21,25 Based on prior literature,6,7,10,21 we
fixed the MB size to ~2 μm, MB concentration to ~1.7×106
bubbles/mL, and sonication time to ~1 minute. Subsequently, we adjusted the voltage and BRR while keeping
the duty cycle constant at 5% to generate different acoustic
powers. Figure 5A shows a disrupted BBB after ~5 minutes by applying a power of ~13.1 W/cm2 (voltage =4 V
and BRR =500 kHz) for 1 minute. We then reduced the
power to ~6.3 W/cm2 (voltage =2.5 V and BRR =500 kHz).
Figure 5B shows the image of the cerebral microvessels
taken after ~20 minutes by applying 1-minute sonication
at this dose. Although there was no visible BBB disruption, the increased permeability was not reversible in
~60 minutes (the measurement was stopped after 60 minutes).
The corresponding BBB permeability measured after 5, 10,
30, and 60 minutes was found to be 27.1×10−7, 23.5×10−7,
23.6×10−7, and 19.6×10−7 cm/s, respectively. These values
are more than ten-fold greater than the control values without
FUS treatment (Table 1). Reducing the power to 3.4 W/cm2
by decreasing the voltage to 1.25 V, there was no change
in the BBB permeability for 60 minutes. However, keeping
the same power of ~6.3 W/cm2, but reducing the voltage to
1.25 V and increasing the BRR to 1,000 kHz, we were able to
achieve a reversible BBB permeability increase in ~30 minutes. Figure 5C shows the image of the cerebral microvessels
after ~20 minutes by applying this reversible acoustic dose
for 1 minute. For comparison, Figure 5D shows the image of
microvessels under the control condition without FUS and
MBs. The fluorescence intensity in the surrounding tissue of
the microvessels was noticeably higher in Figures 5B and
C than that in Figure 5D, indicating more tracers passing
across the microvessel due to the FUS-induced permeability
increase in the presence of MBs.
Figure 6 compares the BBB permeability to dextran155 kDa, under controls and under the treatment of the
optimized FUS (6.3 W/cm 2 when voltage =1.25 V and
BRR =1,000 kHz) in the presence of MBs. The solid line with
filled squares in Figure 6 demonstrates the response of permeability to FUS in the presence of MBs as a function of time.
At 5 minutes post-FUS, the mean permeability increased
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Figure 5 Representative images of the scanning region under various conditions.
Notes: (A) After ~5 minutes post-FUS at the dose of acoustic power density 13.1 W/cm2 (voltage =4 V, BRR =500 kHz) with MB injection. (B) After ~20 minutes post-FUS at
a lower dose of 6.3 W/cm2 (voltage =2.5 V, BRR =500 kHz) with MB injection. (C) After ~20 minutes post-FUS at the same lower dose of 6.3 W/cm2, but reduced voltage =1.25 V
and increased BRR =1,000 kHz, with MB injection. (D) Under control condition, with neither ultrasound sonication nor MB injection.
Abbreviations: BRR, burst repetition rate; FUS, focused ultrasound; MB, microbubble.

Table 1 Cerebral microvessel permeability (P) to TRITC-dextran-155 kDa under various conditions at different time points and the
corresponding corrected P for the RBCs, free dye, and solvent drag
Group

Vessel
radius (µm)
(mean ± SE)

Time
(minutes)

P (measured)
(×10-7 cm/s)
(mean ± SE)

P (corrected
for RBC)
(×10-7 cm/s)

P (corrected
for RBC and
free dye)
(×10-7 cm/s)

Pd (corrected for
RBC, free dye,
and solvent drag)
(×10-7 cm/s)

Pd /P (corrected
for RBC and
free dye)

Ultrasound
and bubble
(n=15)

10.7±1.0

Bubble only
(n=6)

8.1±1.5

Ultrasound
only (n=6)

7.9±1.4

Control
(n=6)

6.8±1.3

5
10
15
20
25
5
25
5
25
0
5
25

19.57±4.49
14.46±2.07
11.02±2.92
5.12±1.30
2.34±0.61
1.40±0.36
1.38±0.47
1.51±0.33
1.24±0.24
1.13±0.19
1.37±0.21
1.72±0.17

17.42
12.87
9.81
4.55
2.08
1.25
1.23
1.34
1.10
1.00
1.22
1.53

17.42
12.87
9.80
4.54
2.07
1.23
1.21
1.33
1.09
0.99
1.21
1.52

16.99
12.86
9.80
4.54
2.07
1.23
1.21
1.33
1.09
0.99
1.21
1.51

0.9752
0.9998
0.9997
0.9994
0.9988
0.9979
0.9979
0.9981
0.9976
0.9974
0.9979
0.9983

Abbreviations: TRITC, tetramethylrhodamine isothiocyanate; RBC, red blood cell; SE, standard error of the mean; Pd, diffusive permeability.
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20
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Ultrasound and bubble (n=15)

*

14

Bubble only (n=6)
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*

12

Control (n=6)

10
8
6
4
2
0

0
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30
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Figure 6 Normalized blood–brain barrier permeability as a function of time.
Notes: The solid line with () is for the treatment by ultrasound of 6.3 W/cm2 (voltage =1.25 V, burst repetition rate =1,000 kHz) in the presence of microbubbles. The
dash-dot-dash line with () is for microbubbles only, with microbubble injection but without ultrasound sonication. The long dashed line with (Δ) is for ultrasound only, with
ultrasound sonication in the absence of microbubbles. The short dashed line with (×) is for the control, with neither ultrasound nor microbubbles. *P-value 0.05 compared
with the control.
Abbreviation: P, permeability.

to (19.6±4.5)×10−7 cm/s (n=15), a significant increase of
14.3 (±4.1)-fold compared with the control (P=0.025).
The mean permeability at 10, 15, 20, and 25 minutes was
(14.5±2.1)×10 −7, (11.0±2.9)×10 −7, (5.1±1.3)×10 −7, and
(2.3±0.6)×10−7 cm/s, respectively, representing increases of
11.5 (±3.3, P=0.001), 6.8 (±2.1, P=0.052), 2.9 (±1.0, P=0.11),
and 1.4 (±0.5, P=0.45)-fold compared with the control group.
At 15 minutes post-FUS, permeability started to recover
values similar to the control; after 25 minutes, permeability
completely returned to the value comparable to the control,
indicating a reversible BBB permeability increase under this
FUS dose in the presence of MBs.
For comparison, the permeability of the control
group (n=6) measured at 0, 5, 10, 15, 20, and 25 minutes
was (1.1±0.2)×10 −7 , (1.4±0.2)×10 −7 , (1.4±0.3)×10 −7 ,
(1.6±0.3)×10−7, (1.8±0.5)×10−7, and (1.7±0.3)×10−7 cm/s,
respectively. The permeability of that under only MB injection without sonication (bubble only, n=6) at 5, 10, 15, 20, and
25 minutes was (1.4±0.4)×10−7, (1.1±0.3)×10−7, (1.2±0.1)×10−7,
(1.3±0.9)×10−7, and (1.4±0.5)×10−7 cm/s, respectively. The
permeability of that under FUS in the absence of MBs
(“ultrasound only”, n=6) at 5, 10, 15, 20, and 25 minutes
was (1.5±0.3)×10 −7 , (1.6±0.4)×10 −7 , (1.3±0.2)×10 −7 ,
(1.1±0.1)×10−7, and (1.2±0.2)×10−7 cm/s, respectively. They
have no significant differences compared with the control
group (P0.6).
Table 1 summarizes the measured permeability and its
corrected value for the RBCs, free dye, and solvent drag
under various conditions at specific times. Since the ratio of
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the diffusive permeability, Pd, to the apparent permeability
corrected after RBC and free dye was more than 97.5%,
the solvent drag contribution to the BBB permeability to
TRITC-dextran-155 kDa was negligible. In contrast, the
solvent drag contribution to the macromolecule permeability is significant in rat mesenteric microvessels due to two
orders of magnitude higher hydraulic conductivity.37 Table
1 also summarizes the mean radius of the microvessels for
each group. Since there was no significant difference in the
BBB permeability between the post-capillary venules and
the capillaries (P0.09), we only gave a mean size for these
two types of microvessels.

Discussion
Nhan et al25 used two-photon microscopy to investigate
the reversible and localized BBB disruption induced by
FUS in the presence of MBs by imaging the cerebral
vasculature during BBB disruption and observing the
extravasation of fluorescently labeled solutes in real-time
in vivo. They found that the threshold acoustic pressure for
a successful induction in BBB disruption was 0.4–0.6 MPa
by combining the MBs with a similar size and a reduced
concentration as those used in the current study. Under
this dose of FUS and the MBs, they observed a visible
BBB disruption in the cerebral microvasculature, which
peaked around 5 minutes, especially for microvessels with
diameter of 10–30 μm. By using a formula in Dreher et al42
they converted the extravasation rate of the fluorescently
labeled solutes to a global permeability index for the
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entire microvasculature, which peaked around 5 minutes
and returned to the baseline in 20 minutes for test solutes,
dextran-10k and -70k, in their study. Their estimated FUSinduced microvasculature permeability index changing
patterns are similar to those in the individual microvessels
under the current study. However, we found that under
0.43 MPa (13.1 W/cm2) of our FUS, the wall of the individual microvessel was disrupted and could not go back to
its baseline (Figure 5A). Even at a reduced power of 0.3 MPa
(6.3 W/cm2) with a voltage of 2.5 V, the permeability of
the individual microvessel could not go back to its baseline
value in ~60 minutes (Figure 5B).
The study from Nhan et al25 was invaluable in narrowing parameter space and defining a consistent methodology.
However, the method in Nhan et al25 had some limitations.
First, being injected via the tail vein, MBs would go back
to the right ventricle of the heart, through the pulmonary
circulation before they go into the systemic circulation and
reach the cerebral microvessels. Along this journey, the MBs
would be trapped in the pulmonary microvessels with smaller
diameters, be diluted, and result in an uncertain concentration
in brain microvessels. This would induce inaccurate assessment of proper parameters for the FUS which can induce
transient BBB permeability increase. Second, the equation
they used to determine the microvasculature permeability
assumes a constant driving force that is represented by the
fluorescent intensity difference between the intravascular and
extravascular spaces along the microvessel. However, tail
vein injection of the fluorescently labeled solutes might not
achieve a constant driving force along the microvessel due to
the plasma clearance. Third, because of the poor drainage in
the brain tissue, the built-up extravascular tracers could not be
cleared out in time and may induce a saturated extravascular
concentration or an extravascular concentration which is
higher than the intravascular one, resulting in an inaccurate
assessment of microvascular permeability by using the formula in Dreher et al.42 Fourth, the region of ~500 μm ×500 μm
from where they determined the permeability, contains many
types of microvessels including arterioles and venules. Postcapillary venules and capillaries were suggested to be more
suitable for permeability study since they are relatively less
contractible or expandable under stimulations.35 These properties are necessary for accurate determination of the BBB
permeability under FUS stimulations.35 Finally, their method
can only give a relative permeability index, not the true
solute permeability for a microvessel defined by the Kedem–
Katchalsky equation.42 To overcome the aforementioned
limitations, in our work we used multiphoton microscopy
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with a higher spatial resolution to accurately determine the
BBB permeability for the individual post-capillary venule or
capillary under the FUS treatment. By injecting both MBs
and fluorescently labeled test solutes through the carotid
artery, we can achieve a more constant concentration in the
cerebral microvessels.
Previous studies have shown that the ultrasound power
(voltage, BRR, and duty cycle), sonication duration, and MB
size and concentration are important factors in controlling
the BBB-disruption levels and determining whether or not
the increased BBB permeability is reversible.6,7,11,15,21,25 Using
MRI, the acoustic power threshold of opening the BBB was
found to be 0.15–0.3 MPa.43 Whereas, the power threshold
using two-photon microscopy was found to be 0.4–0.6 MPa.25
Using the same MB size and concentrations, we found that
the FUS with the same power (0.3 MPa or 6.3 W/cm2) at the
reduced voltage and increased BRR induced a reversible BBB
permeability increase compared with that with higher voltage and lower BRR, which did not exhibit reversibility. The
mechanism responsible for this is unknown. Under this range
of the FUS power, the thermal effect is negligible.44 Other
possible mechanisms for increasing the BBB permeability
by FUS-driven MB activities in the cerebral microvessels
include stable cavitation (stable small oscillation) and inertial
cavitation (large amplitude oscillation).11,45,46 These activities
can generate calcium transient,11,22,47 which may be responsible for the transient increase in the BBB permeability.48
The increased Ca2+ concentration in brain microvascular
endothelial cells by FUS-driven MBs22 is similar to that
induced by bradykinin, histamine, and adenosine triphosphate
(ATP), which are known to transiently increase the BBB
permeability.49,50 The increased magnitude and the temporal
pattern in the permeability of an individual cerebral microvessel induced by the optimized FUS and MBs in the current
study are similar to those in the permeability of an individual
mesenteric microvessel induced by ATP in a study by He
and Curry,51 which also demonstrated the same pattern in
endothelial Ca2+ concentration changes. This similarity suggests the mechanism of calcium transient by the FUS-driven
MB activities in our study. Further investigation needs to be
done to confirm this mechanism.
In summary, in order to find the optimal FUS and MBs
that can induce reversible increase in the BBB permeability for the purpose of brain drug delivery, we employed
minimally invasive multiphoton microscopy to quantify the
BBB permeability to dextran-155 kDa with similar molecular weight to an antibody. We applyed different doses of
FUS in the presence of MBs with an “optimal” size and
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c oncentration. After several trials, we found the optimal dose
of FUS that can transiently increase the BBB permeability.
Our analysis was the first study at the individual microvessel level which provides an accurate in vivo assessment for
the transient BBB permeability change under the treatment
of FUS/MBs. The optimal FUS dose found for the reversible BBB permeability increase without BBB disruption is
reliable and can be applied to future clinical trials in radioimmunotherapy. Our method can also be used to assess the
optimal parameters of FUS/MBs to deliver other types of
therapeutic agents and drug carriers.
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